Breaking News, Collaborations & Alliances

Lilly, AbCellera Dose First Patients with COVID-19 Antibody

Phase 1 study of LY-CoV555 is the world's first study of a potential antibody treatment designed to fight COVID-19

By: Contract Pharma

Contract Pharma Staff

Eli Lilly said patients have been dosed in the world’s first study of a potential antibody treatment designed to fight COVID-19.   This investigational medicine, referred to as LY-CoV555, is the first to emerge from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in just three months after AbCellera and the Vaccine Research Center at the National Institute of Allergy and...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters